The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Open accessAbstract
BACKGROUND: Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose primary lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol. METHODS: We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. The primary study outcome was nonfatal myocardial infarction or death from coronary causes. RESULTS: The median follow-up was 5.1 years. At one year, the mean HDL cholesterol level was 6 percent higher, the mean triglyceride level was 31 percent lower, and the mean total cholesterol level was 4 percent lower in the gemfibrozil group than in the placebo group. LDL cholesterol levels did not differ significantly between the groups. A primary event occurred in 275 of the 1267 patients assigned to placebo (21.7 percent) and in 219 of the 1264 patients assigned to gemfibrozil (17.3 percent). The overall reduction in the risk of an event was 4.4 percentage points, and the reduction in relative risk was 22 percent (95 percent confidence interval, 7 to 35 percent; P=0.006). We observed a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, and stroke (P< 0.001). There were no significant differences in the rates of coronary revascularization, hospitalization for unstable angina, death from any cause, and cancer. CONCLUSIONS: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level. The findings suggest that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, the mean reduction in plasma triglyceride concentration in the fibrate trials was only 20 mg/dL to 50 mg/dL, a fraction of what would be needed to significantly reduce the risk of major vascular events within a shortterm trial.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Treatment with gemfibrozil versus placebo reduced the primary endpoint of death or nonfatal MI by 32% (P = 0.004), mortality by 41% (P = 0.02), and stroke by 40% (P = 0.046).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence supporting the prescription of fibrates for cardiovascular prevention remains debated.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrates decrease triglyceride levels by 30 -50% and sometimes increase HDL cholesterol (165-168).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A sub study was conducted on patients with diabetes participating in the VA-HIT Trial (n=627) compared to those without diabetes (n=142). Following 5 years of treatment with gemfibrozil the investigators observed an average reduction of TG levels by 31% and a corresponding increase in HDLC of 6%. More importantly, these changes were associated with a, statistically significant 22% reduction in”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous fibrate studies in subjects with diabetes10,11 or in those without diabetes13–15 did not address the role of such drugs in patients receiving statin therapy.”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“The ACCORD, LEADER and VA-COOP trials could not confirm that fibrates reduce the incidence of MACE at a 5% significance level, whilst a significant MACE reduction was observed in the FIELD and VA-HIT trials [91–94].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“Studies to date have not demonstrated an overall benefit of fibrates for reduction of cardiovascular or total mortality (165-169).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“For example, the VA-HIT Trial, with a total of 2,531 men with a history of CHD who had low HDLC levels (mean, 32 mg/dl) and low LDLC levels (mean, 111 mg/dl), assigned subjects to receive either 1,200 mg/day of gemfibrozil or placebo. After a 5 year follow-up, treatment with gemfibrozil resulted in a significant 22% reduction in the combined incidence of nonfatal myocardial infarction (MI) and CHD”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Again, there was no significant difference in allcause mortality”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“The results of this study may also help to explain why prior randomized trials evaluating fibrates, which lower plasma triglyceride levels at least partially through the LPL pathway, have failed to consistently demonstrate that lowering triglyceride levels reduces the risk of cardiovascular events.[29][30][31][32][33]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, qualitative changes in LDL cholesterol may be present in the form of small, dense LDL particles which are more atherogenic and may be associated with higher risk of CVD [58-60].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [60]
In the citing paper
“As monotherapy, fibrates likely reduce ASCVD risk.43–45”
From Clinical review on triglycerides (2020) · cites this paper as [45]
In the citing paper
“In the Helsinki Heart Study (HHS) [4] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) [5], administration of gemfibrozil significantly reduced CV event rate, the primary endpoints of the trials.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [5]
In the citing paper
“In some studies, an increase of patient-reported neurocognitive effects has been described [293].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [293]
In the citing paper
“However, the data on other outcome parameters have remained equivocal.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The data from these trials have shown consistent decreases in the rates of non-fatal MI (although often as a result of post-hoc analyses), the effect being most robust in subjects with elevated TG/low HDL-C levels.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The clinical benefits of fibrates in monotherapy are primarily illustrated by four prospective, randomized, placebo-controlled, clinical trials: Helsinki Heart Study (HHS), Veterans Affairs Highdensity lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarction Prevention study (BIP), and FIELD.124 -127”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“Although the Helsinki Heart Study reported a significant reduction in CVD outcomes with gemfibrozil, neither the FIELD nor the ACCORD study showed a reduction in total CVD outcomes.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [266]
In the citing paper
“The results of ESTABLISH642), JAPAN-ACS643), the ZEUS study644), and PRECISE-IVUS645) have shown that in cases stratified into a high-risk category even in secondary prevention, such as ACS or ACS complicated by DM, controlling the LDL-C at a target level of < 70 mg/dL is useful for plaque regression.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“It was reported in the recent PRECISE-IVUS study that decreasing the LDL-C level to < 70 mg/dL using a combination of statin and ezetimibe resulted in a marked plaque volume regression in patients with ACS, compared to those who were treated with statins only645).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“Gemfibrozil has been shown to decrease rates of CVD events in subjects without diabetes (195,196) and in the diabetic subgroup in one of the larger trials (195).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [195]
In the citing paper
“However, additional adjustment for HDL-C and the ratio of apo B to apo AI decreased the predictive ability of on-treatment triglyceride levels, and further adjustment for baseline glucose, BMI, hypertension, T2DM, and smoking eliminated the association.501”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [501]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Mantel N, 1966, Cancer Chemother Rep, 3, 163
Cited by
Sorted by citations
Items 101–200 of 1,017
Aronoff, S., Rosenblatt, S., Braithwaite, S. S., Egan, J. W., Mathisen, A. L., & Schneider, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 626
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 614
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
Carlson, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 591
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D. L., & Glesby, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 578
2016 Chinese guidelines for the management of dyslipidemia in adults.
(2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.01.011 · Cited by 575
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988–2002
SAADDINE, J. B., Cadwell, B. L., Gregg, E. W., Engelgau, M. M., Vinicor, F., Imperatore, G., & Narayan, K. M. V. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00005 · Cited by 561
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.005 · Cited by 531
Sever, P., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 525
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 526
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513
Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C. W., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ASTEROID Investigators (2000) · JAMA · doi:10.1001/jama.284.10.1263 · Cited by 509
Self-citationReaven, G. M. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.002 · Cited by 517
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 503
Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection
Long, A. N., & Dagogo-Jack, S. E. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00434.x · Cited by 516
Pineda‐Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 504
High-sensitivity C-reactive protein
Bassuk, S. S., Rifai, N., & Ridker, P. M. (2004) · Current Problems in Cardiology · doi:10.1016/s0146-2806(04)00074-x · Cited by 493
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel‐Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 489
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Reilly, M. P., & Rader, D. J. (2003) · Circulation · doi:10.1161/01.cir.0000088846.10655.e0 · Cited by 466
Fillmore, N., Mori, J., & Lopaschuk, G. D. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12475 · Cited by 465
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Nitric oxide and atherosclerosis: An update
Claudio Napoli, A., de Nigris, F., Williams‐Ignarro, S., Pignalosa, O., Sica, V., & Ignarro, L. J. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.03.011 · Cited by 471
Bots, M. L., Visseren, F. L. J., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 458
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 456
Secondary Prevention After Coronary Artery Bypass Graft Surgery
Kulik, A., Ruel, M., Jneid, H. M., Ferguson, T. B., Hiratzka, L. F., Ikonomidis, J. S., López-Jiménez, F. A., McNallan, S. M., Patel, M. J., Roger, V. L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000182 · Cited by 457
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.006 · Cited by 451
Dyslipidemia Management in Adults With Diabetes
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s68 · Cited by 444
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 471
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429
Resnick, H. E., Foster, G. L., Bardsley, J. K., & Ratner, R. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1254 · Cited by 431
The metabolic syndrome: requiescat in pace
Reaven, G. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048611 · Cited by 427
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D. J., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 427
Anti-Inflammatory Mechanisms in the Vascular Wall
Tedgui, A., & Mallat, Z. (2001) · Circulation Research · doi:10.1161/hh0901.090440 · Cited by 424
Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schäfers, M. A., Herrgott, I., Mersmann, J., Larmann, J., Hermann, S., Stypmann, J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.607135 · Cited by 414
Barbier, O., Pineda‐Torra, I., Duguay, Y., Blanquart, C., Fruchart, J., Glineur, C., & Staels, B. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 417
Oxidized LDL and HDL: antagonists in atherothrombosis
Mertens, A. C., & Holvoet, P. (2001) · The FASEB Journal · doi:10.1096/fj.01-0273rev · Cited by 414
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Infection and Inflammation‐Induced Proatherogenic Changes of Lipoproteins
Khovidhunkit, W., Memon, R. A., Feingold, K. R., & Grünfeld, C. (2000) · The Journal of Infectious Diseases · doi:10.1086/315611 · Cited by 403
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.04.002 · Cited by 404
Lüscher, T. F., Creager, M. A., Beckman, J. A., & Cosentino, F. (2003) · Circulation · doi:10.1161/01.cir.0000089189.70578.e2 · Cited by 395
Boden, W. E. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01464-8 · Cited by 391
Libby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefèbvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 397
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Luo, R., Su, L.-Y., Li, G., Yang, J., Liu, Q., Yang, L.-X., Zhang, D.-F., Zhou, H., Xu, M., Fan, Y., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1596488 · Cited by 364
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Metabolic outcome during 1 year in newly detected hypertensives
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00022 · Cited by 353
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado‐López, F., & Moore‐Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 358
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 349
Atheroprotective Effects of High-Density Lipoproteins
Assmann, G., & Nofer, J. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152409 · Cited by 345
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000114834.85476.81 · Cited by 342
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 345
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Reverse cholesterol transport and cholesterol efflux in atherosclerosis
Ohashi, R., Mu, H. H., Wang, X., Yao, Q., & Chen, C. (2005) · QJM · doi:10.1093/qjmed/hci136 · Cited by 336
PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes
Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Köenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 336
Couillard, C., Després, J.-P., Lamarche, B., Bergeron, J., Gagnon, J., Leon, A. S., Rao, D. C., Skinner, J. S., Wilmore, J. H., & Bouchard, C. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.092137 · Cited by 331
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 331
American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12514 · Cited by 334
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Racial/ethnic differences in dyslipidemia patterns
Frank, A. T. H., Zhao, B., Jose, P. O., Azar, K. M. J., Fortmann, S. P., & Palaniappan, L. P. (2014) · Circulation · doi:10.1161/circulationaha.113.005757 · Cited by 327
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATION
de Werf, F. V., Ardissino, D., Betriu, A., Cokkinos, D., Falk, E., Fox, K. A. A., Julian, D. G., Lengyel, M., Neumann, F., Ruzyllo, W., et al. (2005) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2005-1-2-62-95 · Cited by 322
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationClinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00006 · Cited by 318
HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study
Després, J., Lemieux, I., Dagenais, G. R., Cantin, B., & Lamarche, B. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00603-1 · Cited by 316
Effects of dietary fructose on plasma lipids in healthy subjects
Bantle, J. P., Raatz, S. K., Thomas, W. T. B., & Georgopoulos, A. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.5.1128 · Cited by 312
Sacco, R. L., Benson, R. T., Kargman, D. E., Boden-Albala, B., Tuck, C., Lin, I.-F., Cheng, J. F., Paik, M. C., Shea, S., & Berglund, L. (2001) · JAMA · doi:10.1001/jama.285.21.2729 · Cited by 311
Durrington, P. N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14234-1 · Cited by 316
Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol
Robins, S. J., Bloomfield, H. E., Faas, F. H., Schaefer, E. J., Elam, M. B., Anderson, J. W., Collins, D. E., & on behalf of the VA-HIT Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1513 · Cited by 308
Self-citationRittershaus, C. W., MILLER, D. P., Thomas, L. J., Picard, M. D., Honan, C. M., Emmett, C. D., Pettey, C. L., Adari, H. Y., Hammond, R. A., Beattie, D. T., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2106 · Cited by 308
Aronow, H. D., Topol, E. J., Roe, M. T., Houghtaling, P. L., Wolski, K. E., Lincoff, A. M., Harrington, R. A., Califf, R. M., Ohman, E. M., Kleiman, N. S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04257-4 · Cited by 308
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
Bates, E., Babb, J. D., Casey, D. E., Cates, C. U., Duckwiler, G., Feldman, T. E., Gray, W. A., Ouriel, K., Peterson, E. D., Rosenfield, K., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.021 · Cited by 309
Self-citationTenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 307
Prevention Conference VI: Diabetes and Cardiovascular Disease
Howard, B. V., Rodríguez, B. L., Bennett, P. H., Harris, M. I., Hamman, R. F., Kuller, L. H., Pearson, T. A., & Wylie‐Rosett, J. (2002) · Circulation · doi:10.1161/01.cir.0000013953.41667.09 · Cited by 307
Wang, Y., Lu, J., Engelstädter, J., Zhang, S., Ding, P., Mao, L., Yuan, Z., Bond, P. L., & Guo, J. (2020) · The ISME Journal · doi:10.1038/s41396-020-0679-2 · Cited by 305
PPARδ is a very low-density lipoprotein sensor in macrophages
Chawla, A., Lee, C.-H., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J., Kang, H., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337331100 · Cited by 305
Metadata
- Authors
- Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., & Wittes, J.
- Affiliations
- Boston University (US)
- West Haven Cooperative Studies Program Coordinating Center (US)
- Veterans Health Administration (US)
- Memphis VA Medical Center (US)
- Tufts University (US)
- Minneapolis VA Medical Center (US)
- Statistics Collaborative (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-08-05
- Volume
- 341
- Issue
- 6
- Pages
- 410-418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2328529137
- Semantic Scholar
- c59834b2e2f45268e79b64cd3316445882b86f66
- Cited by
- 3,439
- References
- 40
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 38 · 2023: 52 · 2022: 41 · 2021: 44 · 2020: 46 · 2019: 56 · 2018: 54 · 2017: 62 · 2016: 69 · 2015: 80 · 2014: 93 · 2013: 129 · 2012: 114
- FWCI
- 242.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- gemfibrozil, secondary prevention, coronary artery disease, low HDL cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, nonfatal myocardial infarction, coronary heart disease mortality, stroke, fibrates, men
- MeSH terms
- Aged, Hypolipidemic Agents, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Hypolipoproteinemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Risk, Triglycerides, Gemfibrozil, Incidence, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
